Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gazyva/obinutuzumab plus chlorambucil versus rituximab plus chlorambucil versus chlorambucil in previously untreated CLL with comorbidities
2009-012476-28Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Obinutuzumab + chlorambucil, Rituximab + chlorambucil and Chlorambucil alone (3 arms). Primary endpoint: Progression-free survival. Started Sep 2009; status: completed.
02
Drugs
obinutuzumabrituximabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2009-012476-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012476-28.